Sugammadex: A novel neuromuscular blocker binding agent

Current Opinion in Anaesthesiology

Volumn 20, Issue 4, 2007, Pages 307-310

  Fields, Aaron M ^a   Vadivelu, Nalini ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclodextrin; Neuromuscular blockade reversal; Sugammadex

Indexed keywords

ANTIEMETIC AGENT; ATRACURIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM;

BRADYCARDIA; DRUG BINDING; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; ENCAPSULATION; HUMAN; HYPOTENSION; LIQUID CHROMATOGRAPHY; LUNG VENTILATION; MASS SPECTROMETRY; MUSCLE RELAXATION; NAUSEA AND VOMITING; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMELLING DISORDER; TASTE DISORDER; TEMPERATURE SENSE;

ANIMALS; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-CYCLODEXTRINS; HUMANS; MACACA MULATTA; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SWINE;

EID: 34447311369     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32814b1612     Document Type: Review

References (18)

1. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45:1806-1816.
2. de Boer HD, van Egmond J, van de Pol F, et al. Time course of action of sugammadex (Org25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth 2006; 97:681-686.
3. de Boer HD, van Egmond J, van de Pol F, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology 2006; 104:718-723.
4. de Boer HD, van Egmond J, van de Pol F, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 96:473-479.
5. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99:632-637; discussion 636A.
6. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41:266-270.
7. Epemolu O, Mayer I, Hope F, et al. Liquid chromatography/mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and Rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 2002; 16:1946-1952.
8. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104:667-674.
9. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96:36-43.
10. Gijsenbergh F,Ramael S,Houwing N, et al. First humanexposure ofOrg25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103:695-703.
11. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuroniumor vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106:283-288. One of the most recent articles that continues the trend of showing safety and efficacy in humans. Contains the majority of the literature published to this point. The study design is excellent and the sample size is large for an early study (n=80).
12. Hemmerling TM, Le N. Brief review: Neuromuscular monitoring: an update for the clinician. Can J Anaesth 2007; 54:58-72.
13. Nava-Ocampo AA, Velazquez-Armenta Y, Moyao-Garcia D, et al. Meta-analysis of the differences in the time to onset of action between rocuronium and vecuronium. Clin Exp Pharmacol Physiol 2006; 33:125-130.
14. Schultz P, Ibsen M, Ostergaard D, et al. Onset and duration of action of rocuronium: from tracheal intubation, through intense block to complete recovery. Acta Anaesthesiol Scand 2001; 45:612-617.
15. Nigrovic V, Bhatt SB, Amann A. First human exposure to Org 25969. Anesthesiology 2006; 105:427; author reply 427.
16. Bettelli G. Which muscle relaxants should be used in day surgery and when. Curr Opin Anaesthesiol 2006; 19:600-605.
17. Piotrowski AJ, Fendler WM. Hyperkalemia and cardiac arrest following succinylcholine administration in a 16-year-old boy with acute nonlymphoblastic leukemia and sepsis. Pediatr Crit Care Med 2007; 8:183-185.
18. Karcioglu O, Arnold J, Topacoglu H, et al. Succinylcholine or rocuronium? A meta-analysis of the effects on intubation conditions. Int J Clin Pract 2006; 60:1638-1646. May be the best argument against using rocuronium and sugammadex for all cases.